Aveanna Healthcare Holdings enters the post-earnings week with the Street turning meaningfully more positive, the stock up nearly 12% on the week to $7.63, and short sellers caught on the wrong side of a 14% gap-up following Q1 results on May 14.
The analyst response to the print has been notably constructive. Stephens & Co. upgraded the stock to Overweight this week, lifting its target from $10 to $11 — the clearest signal that the earnings result shifted the fundamental narrative. RBC Capital raised its target to $10 from $9 while holding Sector Perform. Truist Securities held at Hold but nudged its target up to $9 from $8. The lone dissent came from Barclays, which trimmed its target slightly to $9 from $9.50 while keeping its Overweight rating — a modest adjustment that reads more like housekeeping than conviction selling. With a mean price target of $10.05 against a current price of $7.63, the Street consensus implies roughly 32% upside from here.
The bull case is grounded in EBITDA momentum and deleveraging. Aveanna operates as a diversified home care platform focused on medically complex, high-cost patients — a segment that benefits structurally from cost-containment pressure on the broader healthcare system. Bears flag government reimbursement risk and tight nurse labor markets as the most credible threats, alongside execution risk from the company's acquisition strategy. The company's EV/EBITDA multiple has compressed to 8.8x over the past week — down roughly 0.3 turns — suggesting the market absorbed the post-earnings re-rating quickly rather than letting it run. EPS momentum factor scores rank in the 85th percentile on a 30-day basis and 80th on 90 days, which supports the bull case that estimate revisions are running in the right direction.
Short interest tells a secondary story here. At just 1.4% of the free float, there was never a meaningful short position to squeeze — but the 26% single-day drop on May 19 does indicate some residual capitulation after the earnings move. Short interest had been running higher through the first half of May, briefly touching a weekly peak near May 18, before the latest flush. Borrow conditions have eased with it: cost to borrow has fallen 26% over the week to just 0.35%, among the lowest readings of the past month. Availability is exceptionally loose at over 3,100% of short interest, meaning the lending pool has no constraints on new positioning either way. The ORTEX short score has drifted lower to 34.8 from a local peak of 41.1 on May 18, consistent with the retreat in shorts.
Options positioning normalised after a briefly defensive spike. The put/call ratio jumped to 2.3–2.7 on May 14–15 — likely hedging into the earnings announcement — but has since retreated to 0.61, close to its 20-day average of 0.54. The z-score of 0.10 suggests no unusual directional bet in either direction right now. Close peers PNTG and PRVA both pulled back slightly on the week — down 1.2% and up 1.2% respectively — while AVAH's 12% weekly gain stands out as a clear post-earnings outlier in the group.
The next confirmed earnings date is August 13. Between now and then, the key variable to monitor is how the CMS fraud moratorium — announced the week before the May 14 print — ultimately translates into operational guidance, given the company's reliance on home health agency relationships and referral networks.
See the live data behind this article on ORTEX.
Open AVAH on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
